Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Fsgs Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Fsgs. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Fsgs clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by University of Michigan (2), Alice Bertaina (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Cyclophosphamide 1200 mg/Kg (drug, 1 trial), followed by Fludarabine, Cyclophosphamide 100 mg/Kg.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track Fsgs trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT05508009

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant...

This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney...

Sponsor: Alice BertainaEnrolling: 121 location
RECRUITINGNCT04571658

NEPTUNE Match Study

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney...

Sponsor: University of MichiganEnrolling: 37516 locations
RECRUITINGNCT05650619

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in...

Sponsor: University of MichiganEnrolling: 3001 location

Frequently Asked Questions

There are currently 3 clinical trials for Fsgs, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Fsgs, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Fsgs, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.